Physician profile
Mark Sotsky
NPI 1922070150
$1,093.84
in general payments reported to CMS, 2019-2025
15 companies · $23.81 in 2025
The $23.81 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $13.34 · 2021: $138 · 2022: $125 · 2023: $125 · 2025: $23.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $374.90 | 2021-2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $173.49 | 2019 | |
| Sanofi-Aventis U.S. LLC | $114.61 | 2019 | |
| Preventice Services, LLC | $78.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $71.55 | 2019 | |
| Amgen INC. | $65.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.39 | 2019 | |
| Abbott Laboratories | $35.32 | 2019 | |
| Pfizer INC. | $30.00 | 2019 | |
| Amarin Pharma, INC. | $26.34 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $25.69 | 2019 | |
| Heartflow, INC. | $23.81 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.36 | 2019 | |
| Irhythm Technologies, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sotsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.